TheracosBio is a biopharmaceutical company based in Marlborough, MA, dedicated to providing affordable medications for prevalent diseases. Their mission is to ensure access to new medications for patients with common conditions, believing that affordable pricing can improve public health outcomes. Led by a team of experienced professionals, including President and CEO Brian Connelly, TheracosBio is focused on marketing their FDA-approved medication, Brenzavvy bexagliflozin, which offers a critical and cost-effective option for patients with Type 2 Diabetes.
With a leadership team that brings together expertise in business, law, finance, intellectual property, regulatory affairs, clinical operations, chemistry, manufacturing, quality assurance, and supply chain management, TheracosBio is well-positioned to deliver innovative therapeutic technologies. Their commitment to affordable medications and improved access to the latest treatments sets them apart in the industry, aiming to make a positive impact on public health.
Generated from the website